Alkylating Drug
Cross-indication landscape: approved drugs, active Phase 3, sponsors, and upcoming readouts.
About Alkylating Drug
Alkylating Drug agents represent a cornerstone of cancer chemotherapy, functioning by directly damaging the DNA of cancer cells. Their primary mechanism involves the transfer of an alkyl group to DNA bases, leading to DNA strand breaks, cross-linking, and interference with DNA replication and transcription. This ultimately triggers programmed cell death in rapidly dividing cancer cells. The earliest approved alkylating agent, MYLERAN (busulfan), received its initial approval in 1954 for Chronic Myelogenous Leukemia, marking the beginning of a therapeutic class that would profoundly impact oncology.
Over the decades, this class has been expanded to treat a variety of hematologic malignancies and solid tumors. Approved agents include chlorambucil (LEUKERAN), lomustine (GLEOSTINE), ifosfamide (IFEX), carmustine (GLIADEL), temozolomide (TEMODAR), mechlorethamine hydrochloride (VALCHLOR), trabectedin (YONDELIS), and thiotepa (TEPADINA AND SODIUM CHLORIDE, TEPADINA). These drugs have been instrumental in managing conditions such as Chronic Lymphocytic Leukemia, Lymphoma, Brain Tumors, Testicular Cancer, Glioblastoma, Mycosis Fungoides, Liposarcoma, and Breast Adenocarcinoma.
The field continues to evolve, with ongoing research exploring novel alkylating agents and their application in more complex or refractory cancer types. The development of newer agents aims to improve tumor selectivity, reduce systemic toxicity, and overcome resistance mechanisms. While established agents remain vital, the pipeline reflects a sustained interest in harnessing the DNA-damaging power of alkylating agents, particularly in challenging indications like glioblastoma and small cell lung cancer, suggesting a dynamic future for this therapeutic modality.
18 FDA-approved Alkylating Drug drugs, including BUSULFEX, with 54 active Phase 3 trials across 8 indications from 10 active sponsors. Explore approved drugs, the cross-indication pipeline, sponsors, and the Phase 3 readout calendar below.
Approved Alkylating Drug Drugs
18 totalThe Alkylating Drug class originated with MYLERAN (busulfan) in 1954, developed by WAYLIS THERAP for Chronic Myelogenous Leukemia. This foundational drug paved the way for subsequent agents like LEUKERAN (chlorambucil) in 1957, also from WAYLIS THERAP, targeting Chronic Lymphocytic Leukemia and Lymphoma. Early evolution focused on broadening the spectrum of treatable cancers and refining delivery, leading to drugs like GLEOSTINE (lomustine) and IFEX (ifosfamide) in the 1970s and 80s, which offered utility in brain tumors and testicular cancer, respectively. Later generations, such as TEMODAR (temozolomide) approved in 1999, introduced improved oral bioavailability and efficacy in specific indications like glioblastoma. Individual alkylating drugs differentiate significantly in their clinical profiles. For instance, TEMODAR (temozolomide) offers oral administration and a favorable safety profile for glioblastoma, contrasting with injectable agents like GLIADEL (carmustine) which is delivered directly into the brain cavity for gliomas. Busulfan, available as MYLERAN and BUSULFEX, is primarily used in myeloablative regimens prior to stem cell transplantation, with BUSULFEX offering a more predictable pharmacokinetic profile. Trabectedin (YONDELIS) and lurbinectedin (ZEPZELCA) represent more recent additions, demonstrating activity in specific soft tissue sarcomas and small cell lung cancer, respectively, and exhibiting distinct mechanisms of DNA interaction and cellular effects beyond simple alkylation. Alkylating agents are currently positioned across various lines of therapy, from first-line treatment in certain leukemias and lymphomas to salvage therapy for refractory solid tumors. The availability of generic versions for older agents like busulfan and chlorambucil has increased accessibility. However, newer agents like TEMODAR and ZEPZELCA remain under patent protection, commanding premium pricing. Class-wide toxicities, including myelosuppression, neurotoxicity, and secondary malignancies, necessitate careful patient selection and monitoring. Despite the advent of targeted therapies and immunotherapies, alkylating drugs remain indispensable tools, particularly in indications with limited treatment options.
Alkylating Drug Indications in Trials
Active industry trialsThe current Alkylating Drug pipeline shows significant activity concentrated in specific indications, with Glioblastoma leading the charge with 11 active trials. This reflects the persistent challenge of treating this aggressive brain tumor, where alkylating agents like temozolomide have historically played a role. Small Cell Lung Cancer is another key area, with 4 active trials, followed by broader categories such as Solid Tumors (3 trials), and indications like Leiomyosarcoma and Ewing Sarcoma, each with 2 active trials. This focus highlights the ongoing effort to find effective treatments for difficult-to-treat cancers where alkylating agents might offer a therapeutic advantage. The expansion frontier for alkylating agents extends beyond their original approval spaces, exploring novel patient subpopulations and combination regimens. For example, trials are investigating their use in Ewing Sarcoma and various solid tumors, indicating a search for broader applicability. Combination strategies, pairing alkylating agents with newer modalities like immunotherapy or targeted agents, are a significant trend, aiming to enhance efficacy and overcome resistance. While most agents remain injectable, the development of oral formulations or improved delivery systems continues to be an area of interest for enhancing patient convenience and potentially altering pharmacokinetic profiles. Looking ahead to the next 6-12 months, key readouts are anticipated from trials in Glioblastoma and Small Cell Lung Cancer, which could redefine the standard of care in these settings. Bottleneck disease subsets where alkylating agents have historically struggled, such as certain refractory lymphomas or pancreatic cancers, will be watched for any emerging signals of efficacy from novel combinations or next-generation agents. The current level of activity, with 23 Phase 3 and 29 Phase 2 trials, suggests a robust pipeline, indicating sustained investment and a belief in the continued relevance of this class, particularly when integrated into modern therapeutic strategies.
Top Alkylating Drug Sponsors
Industry trials, any indicationEli Lilly and Company currently leads activity in the Alkylating Drug space with 3 active trials, demonstrating a significant commitment to advancing therapies within this class. This leadership likely stems from a combination of their established oncology portfolio and strategic investments in novel drug development or lifecycle management of existing alkylating agents. Their broad reach across multiple indications suggests a comprehensive approach to leveraging the therapeutic potential of alkylating mechanisms. Key challengers actively competing include Philogen S.p.A., also with 3 active trials, and PharmaMar and AbbVie, each with 2 active trials. Philogen's focus might be on specific targeted delivery systems for alkylating payloads, while PharmaMar, known for YONDELIS and ZEPZELCA, continues to explore indications for their novel agents. AbbVie's involvement suggests they are either developing new alkylating entities or are engaged in combination studies with their existing oncology assets, potentially challenging established originator drugs or exploring new therapeutic niches. The strategic landscape for alkylating drugs is diverse, with sponsors like PharmaMar having a strong presence in Europe and the US. The emergence of generic manufacturers for older agents can impact market dynamics by increasing accessibility and potentially lowering prices, though innovator drugs often maintain market share due to clinical advantages or patent protection. Upcoming catalysts include pivotal trial readouts in indications like Glioblastoma and Small Cell Lung Cancer, which could significantly shift the competitive balance. For investors and BD scouts, monitoring these readouts and understanding the strategic positioning of sponsors—whether focused on first-in-class innovation, lifecycle extension, or generic competition—is crucial for identifying opportunities and assessing risk within this enduring therapeutic class.
Alkylating Drug Phase 3 Readout Calendar Pro
12 Phase 3 trials testing approved Alkylating Drug drugs across 12 indications from 12 sponsors. Earliest readout: Q3 2026.
Coverage: trials whose intervention is an approved Alkylating Drug drug. Pre-approval candidates with development codes are not yet linked.
Methodology
Approved drugs sourced from FDA `pharmClassEpc` (Established Pharmacologic Class) labeling. Active industry trials matched by intervention name (brand or generic) — same coverage approach as our target pages, with the same limitation: pre-approval candidates using development codes won't match until they're approved.
"Active" = RECRUITING / ACTIVE_NOT_RECRUITING / NOT_YET_RECRUITING. Sponsor counts include any company running at least one active industry trial.